Skip to content

Study · Animal study (in vivo) · dog · 2014

3 results

Identification of a novel kisspeptin with high gonadotrophin stimulatory activity in the dog.

Albers-Wolthers KH, de Gier J, Kooistra HS, Rutten VP, van Kooten PJ, de Graaf JJ, Leegwater PA, Millar RP, Schaefers-Okkens AC

Neuroendocrinology5 Jun 2014Cited by 24 (Europe PMC)

PMID24902774 (opens in a new tab)DOI10.1159/000364877 (opens in a new tab)PepBankPUB-24902774
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In anoestrous Beagle bitches, intravenous canine KP-10 from 0.2 μg/kg onwards caused a rapid and robust rise in plasma luteinizing hormone.

    In plain wordsIn female dogs, canine KP-10 caused a fast, strong rise in luteinizing hormone from 0.2 μg/kg upwards.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma luteinizing hormone
    Study

    dogn: not reported in source

    Anoestrous Beagle bitches
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    0.2 to 30 μg/kg · intravenous · single bolusAs given in this study (dog).

    Measurements

    Time to maximum LH
    10 min
    canine KP-10

    Source sentences

    Summary
    From 0.2 μg/kg onwards, canine KP-10 resulted in a rapid and robust rise in plasma LH concentration (max. at 10 min).
    1 context sentence
    Summary · context
    A single bolus of canine KP-10 was administered intravenously to anoestrous Beagle bitches in dosages of 0, 0.1, 0.2, 0.3, 0.5, 1, 5, 10, and 30 μg/kg.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In anoestrous Beagle bitches, intravenous canine KP-10 caused a rapid and robust rise in plasma follicle-stimulating hormone.

    In plain wordsIn female dogs, canine KP-10 caused a fast, strong rise in follicle-stimulating hormone.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma follicle-stimulating hormone
    Study

    dogn: not reported in source

    Anoestrous Beagle bitches
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1 to 30 μg/kg · intravenous · single bolusAs given in this study (dog).

    Measurements

    Time to maximum FSH
    10 to 20 min
    canine KP-10

    Source sentences

    Summary
    KP-10 also resulted in a rapid and robust rise in plasma FSH concentration (max. at 10-20 min).
    1 context sentence
    Summary · context
    A single bolus of canine KP-10 was administered intravenously to anoestrous Beagle bitches in dosages of 0, 0.1, 0.2, 0.3, 0.5, 1, 5, 10, and 30 μg/kg.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In anoestrous Beagle bitches, intravenous canine KP-10 significantly increased plasma oestradiol at 1, 5 and 10 μg/kg.

    In plain wordsIn female dogs, canine KP-10 raised oestradiol at doses of 1, 5 and 10 μg/kg.

    Peptide
    Kisspeptin-10
    Outcome
    IncreasePlasma oestradiol
    Study

    dogn: not reported in source

    Anoestrous Beagle bitches
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    1, 5 and 10 μg/kg · intravenous · single bolusAs given in this study (dog).

    Measurements

    Time to maximum oestradiol
    60 to 90 min
    canine KP-10

    Source sentences

    Summary
    Plasma oestradiol concentration increased significantly after dosages of 1, 5, and 10 μg/kg and reached a maximum at 60-90 min.
    1 context sentence
    Summary · context
    A single bolus of canine KP-10 was administered intravenously to anoestrous Beagle bitches in dosages of 0, 0.1, 0.2, 0.3, 0.5, 1, 5, 10, and 30 μg/kg.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.